Skip to main content
Premium Trial:

Request an Annual Quote

RareCyte PD-L1 Assay

RareCyte has launched its PD-L1 liquid biopsy assay, which the firm said will allow users to evaluate PD-L1 expression on circulating tumor cells in a patient's bloodstream. Customers can use the PD-L1 assay and the AccuCyte-CyteFinder system to process blood to cells for CTC enumeration and PD-L1 biomarker expression analysis, or process blood to plasma for optional cell-free DNA analysis. 

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.